Windlas Biotech Ltd

NSE
WINDLAS •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Windlas Biotech Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
New 52W High today
24.5
TTM PE Ratio
Below industry Median
21.6
Price to Book Ratio
Below industry Median
2.8
Dividend yield 1yr %
Below industry Median
0.7
TTM PEG Ratio
PEG TTM is much higher than 1
1.5
RSI
RSI is mid-range
66.5
MFI
MFI Overbought
74.7

Windlas Biotech Ltd Key Financials

*All values are in ₹ Cr.

Windlas Biotech Ltd shareholding Pattern

Promoter
62.8%
Foreign Institutions
1.4%
Mutual Funds
10.4%
Domestic Institutions
11.7%
Public
24.1%

Windlas Biotech Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
524.20
10Day EMA
513.90
12Day EMA
511.00
20Day EMA
502.00
26Day EMA
496.40
50Day EMA
476.10
100Day EMA
441.00
200Day EMA
392.60
Delivery & Volume
Resistance & Support
539.92
Pivot
Resistance
First Resistance
564.78
Second Resistance
582.87
Third Resistance
607.73
Support
First Support
521.83
Second support
496.97
Third Support
478.88
Relative Strength Index
66.53
Money Flow Index
74.72
MACD
14.57
MACD Signal
11.33
Average True Range
27.19
Average Directional Index
31.71
Rate of Change (21)
17.63
Rate of Change (125)
50.32

Windlas Biotech Ltd Company background

Founded in: 2001
Managing director: Hitesh Windlass
Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, largescale manufacturing services and authentic yet affordable products to its customers and consumers around the world.The company has stateoftheart manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semiurban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products domestic trade generics and overthecounter (OTC) brands and exports.The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders.The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drugdevice combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and lowsolubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and RD, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.
Read More

Windlas Biotech Ltd FAQs

Windlas Biotech Ltd shares are currently priced at 546.7 on NSE and 546.65 on BSE as of 2/21/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Windlas Biotech Ltd [WINDLAS] share was 120.44. The Windlas Biotech Ltd [WINDLAS] share hit a 1-year low of Rs. 220.55 and a 1-year high of Rs. 558.

The market cap of Windlas Biotech Ltd is Rs. 1137.06 Cr. as of 2/21/2024 12:00:00 AM.

The PE ratios of Windlas Biotech Ltd is 21.6 as of 2/21/2024 12:00:00 AM.

The PB ratios of Windlas Biotech Ltd is 2.72 as of 2/21/2024 12:00:00 AM

The Mutual Fund Shareholding was 10.4% at the end of 2/21/2024 12:00:00 AM.

You can easily buy Windlas Biotech Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage